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Abstract Ocellatusin is a new RGD-containing short mono-
meric disintegrin. It is a better inhibitor of K5L1 integrin and a
more potent inducer of the expression of a ligand-induced binding
site epitope on L1 integrin subunit than echistatin. In further
contrast to echistatin, ocellatusin has a direct chemotactic
stimulus on human neutrophils in vitro. The distinct effects of
these two close evolutionarily related disintegrins might be
explained by the presence of methionine-22 and histidine-29 in
the RGD loop of ocellatusin, which are arginine and aspartic
acid, respectively, in echistatin. These mutations may modulate
the conformation and/or recognition properties of the integrin-
binding loop of ocellatusin. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Disintegrins are low molecular weight proteins present in
many Viperidae venoms (for review see [1^3]), initially char-
acterized as potent inhibitors of platelet aggregation via their
interaction with the ¢brinogen receptor, integrin KIIbL3 [4].
The three-dimensional solution structures of a few disintegrins
have been solved using 1H nuclear magnetic resonance spec-
troscopy [5^8]. These investigations revealed that the major
structural element responsible for the disintegrin/integrin in-
teraction is a highly mobile loop joining two short L-strands
and protruding 14^17 Aî from the compact protein core. In
general, the disintegrin family can be divided into two major
subfamilies comprising monomeric and dimeric proteins. Di-
meric disintegrins include both homo- and heterodimers
linked by two disul¢de bonds [9^13].
Monomeric disintegrins have been divided into three groups
according to the length of the polypeptide and the number of
the disul¢de bonds. The ¢rst group includes the short disinte-
grins, which contain four disul¢de bounds [14]. The second
and the most numerous group comprises medium size disinte-
grins with six cystine linkages [3]. The third group of long
disintegrins contains peptides crosslinked by seven disul¢de
bonds [15]. Monomeric disintegrins mostly express an RGD
sequence at the apex of the integrin-binding loop and are
inhibitors of the so-called RGD-dependent integrins, includ-
ing the integrins KIIbL3, KvL3 and K5L1. These three integrins
play vital roles in many physiological processes such as ho-
meostasis and thrombosis [16], angiogenesis, in£ammation,
bone resorption and wound healing [17], cell growth and or-
gan development [18]. Blocking of these integrins by selective
inhibitors would be of clinical relevance in the treatment of
disorders such as platelet-induced thromboembolism and the
progression of cancer. Monomeric disintegrins interact with
their integrin target with di¡erent selectivity, and comparative
experiments with native [19,20], synthetic [21] and recombi-
nant [22,23] disintegrins have revealed that their integrin-bind-
ing characteristics depend on amino acids £anking the RGD
sequence. Studies on two short disintegrins, echistatin (iso-
lated from the venom of Echis sochureki) and eristostatin
(from the venom of the viper Eristocophis macmahoni),
showed that the type and position of the amino acids £anking
the RGD motif determine the shape of the RGD loop [14],
resulting in the speci¢c recognition of integrin receptors by
these disintegrins [19,21,22]. Eristostatin is a very potent and
selective inhibitor of KIIbL3, whereas echistatin potently inhib-
its the binding of all the three RGD-dependent integrins to
their natural ligands. Conversion by recombinant techniques
of the active loop of echistatin into that of eristostatin re-
sulted in an increased potency of this hybrid disintegrin in
the inhibition of KIIbL3 integrin and in the loss of the inhib-
itory activity towards KvL3 and K5L1 integrins [22].
Disintegrins are potent inducers of conformational changes
in both subunits of integrins and lead to the expression of an
LIBS (ligand-induced binding site) epitope. Truncation of the
C-terminal residues of echistatin resulted in a signi¢cant de-
crease in its ability to induce the expression of the LIBS epi-
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tope on both the L3 and L1 integrin subunits [22,23], strongly
indicating that the potency of LIBS epitope induction is asso-
ciated with this part of the disintegrin molecule.
Here, we report the amino acid sequence and biological
characterization of the short monomeric disintegrin, ocellatu-
sin, which was isolated from the venom of Echis ocellatus.
This new protein possesses high homology with echistatin
and eristostatin, but exhibits di¡erent potency and selectivity
against the RGD-dependent integrins, which, we hypothesize,
are associated with di¡erences in the amino acid sequence of
the RGD loop.
2. Materials and methods
2.1. Materials
Monoclonal antibody Mab62, provided by Dr. Mark Ginsberg
(Scripps Research Institute, La Jolla, CA, USA), is speci¢c for
LIBS2, an epitope in the C-terminal region of the extracellular do-
main of the L3 integrin subunit [24]. The monoclonal antibody 9EG7,
which recognizes an LIBS epitope on the L1 subunit [25], was pur-
chased from Pharmingen (San Diego, CA, USA). Highly puri¢ed ¢-
brinogen was a gift from Dr. A. Budzynski (Temple University Phil-
adelphia, PA, USA). Human ¢bronectin and vitronectin were
purchased from Sigma (St. Louis, MO, USA) and Chemicon (Teme-
cula, CA, USA), respectively.
Cell lines: A5 cells - Chinese hamster ovary cells transfected with
human KIIbL3 integrin [26], were kindly provided by Dr. M. Ginsberg
(Scripps Research Institute, La Jolla, CA, USA). HS.939T cells ex-
pressing KvL3, and K562 cells expressing K5L1 were purchased from
ATCC (Manassas, VA, USA).
2.2. Puri¢cation of disintegrins
Ocellatusin and echistatin were puri¢ed from the whole venoms of
E. ocellatus and E. sochureki, respectively. Lyophilized E. sochureki
venom was purchased from Latoxan (France). A pool of venom was
collected from 150 wild-caught specimens of Nigerian E. ocellatus
snakes of all ages and of both sexes maintained in the herpetarium
of the Liverpool School of Tropical Medicine. Venom was lyophilized
and stored at 4‡C in a dark bottle before use. The venoms were
dissolved in 0.1% tri£uoroacetic acid (TFA) and subjected to high-
performance liquid chromatography (HPLC) on a C18 reverse-phase
column as described [11]. Ocellatusin and echistatin were eluted with
about 30% acetonitrile. Fractions containing the disintegrins were
rechromatographed using the same column and developed with a
‘£atter’ acetonitrile gradient. The purity of the disintegrins was as-
sessed by SDS^PAGE and matrix-assisted laser desorption ioniza-
tion-time of £ight (MALDI-TOF) mass spectrometry (using an Ap-
plied Biosystems DE-Pro spectrometer at the mass spectrometry
facility of the Wistar Institute, University of Pennsylvania). Protein
concentration was determined with the bicinchoninic acid protein
quanti¢cation kit (Pierce Co.) with bovine serum albumin as a stan-
dard.
2.3. Structural characterization of ocellatusin
Puri¢ed ocellatusin was reduced and alkylated as described previ-
ously [11]. S-pyridylethylated (PE-) ocellatusin was initially character-
ized by N-terminal sequencing (using either an Applied Biosystems
477A or Beckman Porton LF-3000 instrument), amino acid analysis
(using a Beckman Gold Amino Acid Analyzer after sample hydrolysis
with 6 N HCl for 24 h at 110‡C) and mass spectrometry (as above).
For quantitation of the sulfhydryl groups, native ocellatusin (2 mg/ml
in 100 mM Tris^HCl, pH 9.0, 150 mM NaCl, 6 M guanidine hydro-
chloride) was heat-denatured (1 min at 100‡ C), cooled at room tem-
perature, and treated with iodoacetamide (10-fold molar excess over
total cysteine content determined by amino acid analysis) for 1 h at
room temperature. Carboxymethylcysteine was determined by amino
acid analysis. The primary structure of ocellatusin was deduced from
the N-terminal sequence analysis of the overlapping peptides obtained
by degradation with CNBr (10 mg/ml protein and 100 mg/ml CNBr in
70% (v/v) formic acid for 6 h at room temperature, under N2 atmos-
phere and in the dark). The peptides were separated by a reverse-
phase HPLC using a 4U250 mm C18 (5 Wm particle size) Lichrospher
RP100 (Merck) column eluted at 1 ml/min with a linear gradient of
0.1% TFA in water (solution A) and 0.1% TFA in acetonitrile (solu-
tion B).
2.4. Cell adhesion studies
Adhesion studies of cultured cells labeled with 5-chloromethyl£uo-
rescein diacetate (CMFDA) were performed as described previously
[21].
2.5. Platelet aggregation assay
Platelet aggregation assays were performed using platelet rich plas-
Fig. 1. Comparison of the amino acid sequences of the short monomeric disintegrins ocellatusin (E. ocellatus, this work), echistatin (E. sochure-
ki) [30], eristostatin ( = eristocophin) from E. macmahoni [29], multisquamatin (Echis multisquamatus) [28], pyramidin A ( = echistatin L) and pyr-
amidin B ( = echistatin Q) from Echis pyramidum leakeyi [28,32], leucogastin A and leucogastin B from Echis leucogaster [28]. The cysteines are
underlined and the RGD motifs are in italics. Asterisks below the multiple sequence alignment indicate residues that are absolutely conserved
among this group of short monomeric disintegrins.
FEBS 25722 8-2-02
J.B. Smith et al./FEBS Letters 512 (2002) 111^115112
ma isolated from human blood in the presence of 0.4% sodium citrate
as described earlier [21].
2.6. Neutrophil chemotaxis assay
The neutrophil chemotaxis assay was performed as described pre-
viously for other disintegrins [27]. Brie£y, polymorphonuclear neutro-
phils (PMNs) isolated from the EDTA-treated peripheral venous
blood obtained from healthy volunteers were suspended at a concen-
tration of 106 cells/ml in RPMI (Roswell Park Memorial Institute)
medium 1640 (Invitrogen Life Techn.). This suspension was added to
the top wells of the Boyden chamber (containing 5 Wm PVP-free
polycarbonate ¢lter) and allowed to migrate for 60 min at 37‡C in
a 5% CO2 atmosphere into bottom wells containing the chemoattrac-
tants (disintegrins). In the next step, the ¢lters were removed from the
chambers, ¢xed, and stained using a Di¡-Quick stain kit (Baxter
Travenol Laboratories, Mississauga, ON, Canada). PMNs that mi-
grated through the membrane were counted using light microscopy.
Results represent the mean number of neutrophils per ¢eld obtained
in three di¡erent experiments. The migration of PMNs towards RPMI
medium alone was used as the negative control.
3. Results and discussion
N-terminal sequencing and mass spectrometric analysis of
native ocellatusin yielded the single amino acid sequence
DCESGPCCDNCKFLKEGTICKMARGDNMHDYC and
an isotope-averaged molecular mass of 5598 þ 2 Da. Amino
acid analysis of non-reduced, iodoacetamide-treated ocellatu-
sin showed that it did not contain free sulfhydryl groups.
After reduction and alkylation with vinylpyridine, a single
peak was isolated by reverse-phase HPLC. The molecular
mass of PE-ocellatusin determined by MALDI-TOF mass
spectrometry was 6446 þ 1 Da. The mass di¡erence of 848
Da clearly showed that ocellatusin contained eight cysteine
residues involved in the formation of four disul¢de bonds.
The complete primary structure (Fig. 1) of ocellatusin was
established by N-terminal sequence analysis of the native pro-
tein and HPLC-isolated CNBr-derived fragments. It contains
50 residues and its calculated isotope-averaged molecular
mass (5597.2 Da) is in excellent agreement with the experi-
mentally determined mass. The amino acid sequence of ocel-
latusin displays high homology with other short monomeric
disintegrins isolated from Echis and Eristocophis snake ven-
oms (Fig. 1). In particular, ocellatusin and echistatin are 80%
identical. Further, during the course of our study, Okuda et
al. [28] reported the amino acid sequence of ocellatin isolated
from the venom of E. ocellatus. Ocellatin and ocellatusin are
identical, except for the latter having Asp in position 30 in
place of a histidine in the former, and for the presence of a C-
terminal threonine in ocellatusin, which is absent in ocellatin.
Although ocellatusin and ocellatin might be isoforms, the mo-
lecular mass of ocellatin, which would clarify this point, was
not reported [28].
The IC50 for ADP-induced platelet aggregation of ocellatu-
sin was 168 þ 20 nM, which is similar to that reported for the
other short monomeric disintegrins isolated from the genus
Echis (Fig. 1), e.g. ocellatin (104 þ 33 nM), multisquamatin
(93 þ 8 nM), pyramidin A (160 þ 21 nM), pyramidin B
(233 þ 48 nM), leucogastin A (360 þ 67 nM), leucogastin B
(170 þ 41 nM) [28], echistatin (136 þ 29 nM). These disinte-
grins are signi¢cantly less active than eristostatin
(IC50 = 59 þ 22 nM) [29], a short disintegrin isolated from
the venom of E. macmahoni. Amino acids £anking the
Fig. 2. Comparison of the cell adhesion inhibitory activities of ocellatusin and echistatin. The e¡ect of ocellatusin (¢lled circles) and echistatin
(open circles) on the adhesion of K562 cells to immobilized ¢bronectin (A) and A5 cells to immobilized ¢brinogen (B) and HS.939T to immo-
bilized vitronectin (C) was tested using CMFDA-labeled cells. Percentage of inhibition was calculated in relation to control sample not exposed
to disintegrins. The error bars represent standard deviation from three independent experiments.
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RGD motif modulate the integrin inhibitory potency and se-
lectivity of disintegrins [19^23]. Ocellatusin (IC50 = 77.0 þ 17.1
nM) was only slightly less active than echistatin
(IC50 = 48.5 þ 4.9 nM) inhibiting the adhesion of A5 cells to
immobilized ¢brinogen (Fig. 2B). No signi¢cant di¡erence in
the inhibitory e¡ect on the adhesion of HS.939T cells, a hu-
man melanoma cell line which highly expresses KvL3 integrin,
to immobilized vitronectin was observed between echistatin
(IC50 = 118.2 þ 6.4 nM) and ocellatusin (IC50 = 106.2 þ 15.2
nM, Fig. 2C). These data suggest that di¡erences in the amino
acid sequences of the RGD loops of ocellatusin and echistatin
do not a¡ect their ability to inhibit L3 integrins (KIIbL3 and
KvL3). On the other hand, Fig. 2A shows that ocellatusin
(IC50 = 7.0 þ 1.2 nM) was over one order of magnitude more
active than echistatin (IC50 = 54.2 þ 9.3 nM) in inhibiting the
adhesion of K562 cells to immobilized ¢bronectin mediated
by integrin K5L1.
The RGD loops of ocellatusin and echistatin [30] di¡er in
three amino acids, which are (ocellatusin/echistatin) Met22/
Arg, Asn27/Asp, and His29/Asp. The inhibitory activities to-
wards integrin K5L1 of a number of disintegrins containing
RGDD or RGDN are indistinguishable [20,22]. On the other
hand, the substitutions at positions 22 and 29 are non-con-
served and may signi¢cantly a¡ect the physicochemical prop-
erties (charge, shape) of the RGD loop and contribute to the
enhanced K5L1 inhibitory potency of ocellatusin over echista-
tin. However, at present it cannot be ruled out that other
amino acid di¡erences between ocellatusin and echistatin
also contribute to the enhanced K5L1 speci¢city of ocellatusin.
The more powerful antagonistic e¡ect of ocellatusin com-
pared with echistatin on the K5L1 integrin was also re£ected at
the level of the expression of LIBS. Fig. 3A shows that lower
concentrations of ocellatusin than echistatin were needed to
induce maximal expression of the LIBS epitope recognized by
the monoclonal antibody 9EG7 (anti-L1). Noteworthy, both
disintegrins induced almost equally expression of LIBS on L3
integrin subunit recognized by the monoclonal antibody
Mab62 (Fig. 3B). The ability of disintegrins to induce LIBS
expression depends on both the RGD loop and the C-termi-
nus [21,22]. Disintegrins with a truncated C-terminus or with
a mutated RGD motif lack the activity to express LIBS epi-
topes on both L3 and L1 integrin subunits. The fact that ocel-
latusin exhibits similar to echistatin LIBS expression activity
on L3 integrins suggests that increased LIBS epitope expres-
sion on the L1 subunit correlates with the higher a⁄nity of
ocellatusin to the K5L1 integrin.
It is important to note that ocellatusin, but not echistatin,
signi¢cantly induced chemotaxis of human neutrophils (Fig.
4) in a dose-dependent manner. Although the possibility that
this e¡ect might be linked to the interaction of ocellatusin
with a neutrophil receptor that is not a target of echistatin
cannot be ruled out, we favor the hypothesis that the chemo-
taxic activity may be related to its higher a⁄nity for the K5L1
integrin.
In conclusion, we report a new short monomeric disintegrin
isolated from the venom of E. ocellatus from West Africa.
Another member of this family, echistatin, was previously
isolated from the venom of a snake of the same genus, E.
sochureki [30] from a di¡erent geographical region (Afghani-
stan, Pakistan and India). Ocellatusin di¡ers from echistatin
in possessing (i) enhanced a⁄nity for integrin K5L1 ; (ii) higher
LIBS expression on L1 ; and (iii) a chemotactic e¡ect on hu-
Fig. 3. E¡ect of ocellatusin and echistatin on LIBS expression. The ability to trigger LIBS expression was assessed for ocellatusin (¢lled circles)
and echistatin (open circles) in an adhesion assay of K562 cells to immobilized 9EG7 monoclonal antibody (A) and A5 cells to immobilized
Mab62 monoclonal antibody (B). 9EG7 recognizes LIBS epitope on the L1 subunit of K5L1 integrin and Mab62 binds to LIBS epitope on the
L3 subunit of KIIbL3 integrin. The error bars represent standard deviation from three experiments.
Fig. 4. E¡ect of ocellatusin (¢lled circles) and echistatin (open
circles) on human neutrophil chemotaxis in vitro. Cells were allowed
to migrate in the Boyden chamber towards medium alone (open
squares), ocellatusin (¢lled circles) or echistatin (open circles). Data
show mean þ standard deviation from three independent experi-
ments.
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man neutrophils. Changes in venom composition have previ-
ously been shown to re£ect di¡erent prey species [31] and it
may be that this is the case here. The di¡erence in the chemo-
tactic e¡ects of ocellatusin and echistatin on neutrophils may
suggest a di¡erent mechanism of venom action.
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